Eli Lilly And Company ((LLY)), Loxo Oncology Inc ((LOXO)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Eli Lilly and Company, in collaboration with Loxo Oncology Inc., is conducting a Phase 3 clinical trial titled A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322). The study aims to assess the efficacy and safety of adding pirtobrutinib to the existing treatment regimen of venetoclax and rituximab for patients with previously treated CLL/SLL.
The trial tests two treatment arms: Arm A involves the experimental combination of pirtobrutinib with venetoclax and rituximab, while Arm B serves as the active comparator with venetoclax and rituximab alone. Pirtobrutinib and venetoclax are administered orally, and rituximab is given intravenously.
This interventional study employs a randomized, parallel assignment model without masking, focusing on treatment as its primary purpose. Participants are randomly allocated to one of the two arms to compare outcomes effectively.
The study began on September 20, 2021, and is currently active but not recruiting new participants. The last update was submitted on July 1, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
The outcome of this trial could significantly influence Eli Lilly and Loxo Oncology’s market position, potentially boosting investor confidence if results are favorable. The study’s progress is particularly relevant in the competitive oncology market, where advancements can lead to substantial shifts in stock performance.
The study is ongoing, with further details available on the ClinicalTrials portal.